Nascent Kicks Off Phase II with New Production

In the realm of clinical-stage biotechnology, Nascent Biotech, Inc. is a company that stands out with its focus on developing monoclonal antibodies to combat various forms of cancer. The company is currently gearing up for a new manufacturing phase to ensure the potency of its key drug, Pritumumab (PTB), for the upcoming Phase II clinical trials. This initiative underscores the company's dedication to the wellbeing of its investors, partners, shareholders, and prospective patients.

The CEO of Nascent Biotech, Sean Carrick, emphasizes the importance of a careful and meticulous approach during this critical phase. He states that while delays may be inconvenient, the priority is to maximize patient outcomes and enhance long-term shareholder value. Carrick also highlights that the company is not taking any shortcuts and is actively engaging with potential study sites to facilitate patient recruitment and streamline processes for the imminent dosing phase.

The decision to embark on a fresh manufacturing run comes on the heels of a successful Phase I trial. This trial involved 15 patients with brain tumors, predominantly Glioblastoma, the most challenging to treat. The study demonstrated no dose-related toxicities and established the safety of PTB up to a dosage of 16.2 mg/kg every 7 days. Remarkably, one patient showed a significant response, with a reduction in tumor lesions lasting for over 21 months.

Carrick further explains that Phase II will concentrate on the clinical outcomes, building upon the excellent safety profile established in Phase I. The management anticipates that some research sites will be ready to commence Phase II testing by late summer, with patient involvement expected later in the year.

Nascent Biotech, Inc. is a phase 2 clinical-stage biotech company that is pioneering the development of human monoclonal antibodies for cancer treatment. The company's lead candidate, Pritumumab (PTB), has already advanced to Phase 2 clinical trials for brain cancer treatment. Nascent Biotech is committed to making a significant impact on the global healthcare landscape by providing innovative solutions for cancer patients.